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 Continuous deliverySince the first description of the “shaking palsy” by James Parkinson in 1817,1 our
knowledge and understanding of Parkinson’s disease (PD) has been evolving.2 The
degeneration of dopamine neurons in the substantia nigra leads to the primary motor
symptoms of PD, although changes throughout the brain have been reported, ac-
counting for both motor and nonmotor symptoms (NMS) of the disease.3 The patho-
genesis of the loss of dopamine neurons remains unclear and studies have reported
both genetic and environmental risk factors.4 To date, the majority of treatments for
PD have focused on the fact that degeneration of the dopaminergic nigrostriatal path-
ways results in the loss of motor control and replenishing dopamine would reverse, at
least temporarily, the symptoms of PD.5
Dopamine replacement therapy with levodopa results in significant clinical improve-
ment and remains the mainstay for treating the motor deficits related to PD.6 However,
levodopa can lead to motor complications including dyskinesia andmotor fluctuations,
such as the re-emergence of motor symptoms at the end of the levodopa dosing win-
dow (wearing off), unpredictable loss of symptom control, and dose failures. The short
half-life of levodopa produces a pulsatile stimulation of striatal dopamine receptors,
which has been hypothesized to contribute to the occurrence of levodopa-induced
motor complications.2,6 Furthermore, observation of the tonic firing of dopaminergic
neurons in animal studies suggested that continuous dopaminergic stimulation may
better control the symptoms of PD without the development of motor complications.7
The discovery of the dopaminergic receptors involved in striatal motor control led to
the development of more specific dopamine agonists for the treatment of PD. Due to
their longer half-life, dopamine agonists have been shown to reduce the occurrence of
levodopa-induced motor fluctuations and dyskinesia.2,8 Dopamine agonists are
divided into ergot-derived and non-ergot-derived agents. The first dopamine agonists
to become available, the ergot agonists, include bromocriptine, cabergoline, pergo-
lide, and lisuride. The non-ergot-derived dopamine agonists include pramipexole, ro-
pinirole, rotigotine, and apomorphine. Due to the risk of fibrotic valvular heart disease
with ergot agonists, they have largely been replaced by the nonergot agonists that
have not been reported to cause these problems.9
Managing the motor symptoms associated with PD continues to be the primary
focus of treatment; however, NMS can cause significant disability and are often under-
recognized and undertreated.10 The NMS of PD include sleep and mood disorders,
pain, autonomic dysfunction, and cognitive abnormalities.11 Nearly all PD patients
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Editorialviiipain (38%), and insomnia (37%).12 These NMS can severely affect patients’ quality of
life and can often be more disabling than the motor symptoms of PD.13,14
The purpose of this supplement is to provide an overview of the pathophysiology
and management of the motor and NMS of PD and the importance of continuous
dopaminergic stimulation, as well as summarize the pharmacologic development
and clinical history of the rotigotine transdermal system for the treatment of early
and advanced-stage PD. Rotigotine is a nonergot dopamine agonist. The rotigotine
transdermal system was developed to provide continuous dopaminergic drug delivery
over 24 hours via a patch worn on the skin, with the objective of reducing PD symp-
toms and maintaining stable control of symptoms throughout the day. Transdermal
delivery differentiates rotigotine from the orally administered dopamine agonists, pra-
mipexole and ropinirole, and the subcutaneously injected apomorphine.
The articles in this supplement address specific topics related to the treatment of
motor and NMS of PD with the rotigotine transdermal system. The article by Sung
and Nicholas discusses NMS and their relationship with the pathologic nature of PD
as well as the assessment of NMS and evidence-based treatment options. The article
by Jenner provides an overview of the pathophysiology of dyskinesia and motor fluc-
tuations in patients treated with levodopa. He also discusses the concept of contin-
uous drug delivery and how it may alleviate levodopa-induced motor complications,
using the rotigotine transdermal system as an example. The article by Cheryl Waters
reviews the development of the rotigotine transdermal system for the treatment of PD
including preclinical and clinical pharmacokinetics and pharmacodynamics. Finally,
Lyons and Pahwa provide an overview of the clinical trial data demonstrating the
efficacy of rotigotine in the treatment of PD. The discussion presents the clinical
data supporting the role of rotigotine for treating the motor symptoms of the disease
in patients with early and more advanced PD as well as the results of a clinical trial
examining the effects of rotigotine on NMS of PD.
In summary, the objective of this supplement is to provide the clinician with an
understanding of the relationship between the motor and NMS of PD and to provide
a basis for the role of the rotigotine transdermal system in the treatment of their
patients with PD.
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